Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rongrui Liu is active.

Publication


Featured researches published by Rongrui Liu.


Clinical Cancer Research | 2017

PIK3CA mutations contribute to acquired cetuximab resistance in metastatic colorectal cancer patients

Jian Ming Xu; Yan Wang; You-Liang Wang; Tao Liu; Ming Ni; Man-Sheng Li; Li Lin; Fei-Jiao Ge; Chun Gong; Jun-Yan Gu; Ru Jia; He-Fei Wang; Yu Ling Chen; Rongrui Liu; Chuanhua Zhao; Zhaoli Tan; Yang Jin; Yunping Zhu; Shuji Ogino; Zhi Rong Qian

Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of the EGFR signaling pathway in conferring acquired resistance has not been extensively investigated. Experimental Design: Using circulating tumor DNA (ctDNA) from patients with mCRC and with acquired cetuximab resistance, we developed a targeted amplicon ultra-deep sequencing method to screen for low-abundance somatic mutations in a panel of genes that encode components of the EGFR signaling pathway. Mutations with significantly increased variant frequencies upon disease progression were selected by using quartile analysis. The functional consequences of the identified mutations were validated in cultured cells. Results: We analyzed 32 patients with acquired cetuximab resistance in a development cohort. Of them, seven (22%) carried five novel PIK3CA mutations, whereas eight (25%) carried previously reported KRAS mutations. Functional studies showed that novel PIK3CA mutations (all in exon 19; p.K944N, p.F930S, p.V955G, p.V955I, and p.K966E) promote cell viability in the presence of cetuximab. Only one novel PIK3CA mutation (p.K944N) was verified in one of the 27 patients with acquired resistance in a validation cohort, simultaneous KRAS and PIK3CA hotspot mutations were detected in two patients. Among the above 59 acquired resistance patients, those with PIK3CA or RAS mutations detected in ctDNA showed a pronounced decrease in progression-free survival than patients with no mutation. Conclusions: The PIK3CA mutations may potentially contribute to acquired cetuximab resistance in patients with mCRC. Clin Cancer Res; 23(16); 4602–16. ©2017 AACR.


BMC Cancer | 2016

DNA in serum extracellular vesicles is stable under different storage conditions

Yang Jin; Keyan Chen; Zongying Wang; Yan Wang; Jianzhi Liu; Li Lin; Yong Shao; Lihua Gao; Huihui Yin; Cong Cui; Zhaoli Tan; Liejun Liu; Chuanhua Zhao; Gairong Zhang; Ru Jia; Lijuan Du; Yu-Ling Chen; Rongrui Liu; Jianming Xu; Xianwen Hu; You-Liang Wang


Clinical & Translational Oncology | 2016

Patients with brain metastases derived from gastrointestinal cancer: clinical characteristics and prognostic factors

Li Lin; Chuanhua Zhao; Fei-Jiao Ge; Yan Wang; Yu-Ling Chen; Rongrui Liu; Ru Jia; Liejun Liu; Jianzhi Liu; Jian Ming Xu


Oncotarget | 2015

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma

Chuanhua Zhao; Li Lin; Jianzhi Liu; Rongrui Liu; Yu-Ling Chen; Fei-Jiao Ge; Ru Jia; Yang Jin; Yan Wang; Jianming Xu


International Journal of Clinical and Experimental Medicine | 2014

Diffuse alveolar hemorrhage after erlotinib combined with concurrent chemoradiotherapy in a patient with esophageal carcinoma

Chuanhua Zhao; Rongrui Liu; Li Lin; Jianzhi Liu; Fei-Jiao Ge; Shan-Shan Li; Chenyang Ye; Yu-Ling Chen; Yan Wang; Jianming Xu


Journal of Clinical Oncology | 2018

Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.

Jianming Xu; Yun Zhang; Ru Jia; Yan Wang; Rongrui Liu; Gairong Zhang; Chuanhua Zhao; Yaoyue Zhang; Jianjun Zou; Quanren Wang


Journal of Clinical Oncology | 2018

Postradiation ctDNA status as a prognostic factor in locally advanced esophageal squamous cell carcinoma.

Ru Jia; Pansong Li; Chuanhua Zhao; Yan Wang; Rongrui Liu; Lianpeng Chang; Yanfang Guan; Xin Yi; Jianming Xu


Journal of Clinical Oncology | 2018

Circulating tumor DNA clone analysis to predict disease progression/indicates trastuzumab-resistant mechanism in advanced gastric cancer.

Yan Wang; Lianpeng Chang; Yu-Bo Jiang; Ru Jia; Rongrong Chen; Jin Li; Xuefeng Xia; Yanfang Guan; Rongrui Liu; Chuanhua Zhao; Yun Zhang; Xin Yi; Jianming Xu


Journal of Clinical Oncology | 2018

A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.

Jianming Xu; Ru Jia; Yan Wang; Rongrui Liu; Chuanhua Zhao; Hui Zhou; Linxinyu Xu; Xuan Kong


Clinical Cancer Research | 2018

Anti-PD-1 Antibody SHR-1210 combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Jian Ming Xu; Yun Zhang; Ru Jia; Chun Yan Yue; Lianpeng Chang; Rongrui Liu; Gairong Zhang; Chuan Hua Zhao; Yao Yue Zhang; Chun Xia Chen; Yan Wang; Xin Yi; Zhiyuan Hu; Jian Jun Zou; Quan Ren Wang

Collaboration


Dive into the Rongrui Liu's collaboration.

Top Co-Authors

Avatar

Yan Wang

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Chuanhua Zhao

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Ru Jia

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Jianming Xu

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Li Lin

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Fei-Jiao Ge

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Jianzhi Liu

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Yu-Ling Chen

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Gairong Zhang

Academy of Military Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Jian Ming Xu

Academy of Military Medical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge